APOE, APOE promoter, and Tau genotypes and risk for concussion in college athletes.

OBJECTIVE: To investigate associations of APOE, APOE promoter (G-219T), and tau protein exon 6 polymorphisms (47 and 53) and a history of self-reported concussion in college athletes. DESIGN: Multi-center cross-sectional study. SETTING: Male football and male and female soccer programs at the University of South Carolina, Jacksonville University, Benedict College, and the College of Charleston. PARTICIPANTS: Active 18- to 30-year-old (n = 195) intercollegiate male football players and male and female soccer players during 2001 and 2002. ASSESSMENT OF RISK FACTORS: Written questionnaires and blood or mouthwash samples for DNA for genotyping by RFLP/PCR. MAIN OUTCOME MEASUREMENT: Self-reported history of concussions over the previous 8 years. RESULTS: A statistically significant, nearly 3-fold increase in risk of a history of concussion for those with the APOE promoter G-219T TT genotype relative to the GG genotype (OR, 2.8; 95% CI, 1.1 to 6.9) adjusted for age, sport, school, and years in their primary sport, a finding that was stronger for Cantu grade 2 and 3 concussions. CONCLUSIONS: These results suggest that college athletes with an APOE promoter G-219T TT genotype may be at increased risk for having a history of concussions, especially more severe concussions. Although there was some support for the possibility that the tau 53 polymorphism may be associated with increased risk of prior concussion (OR, 2.1; 95% CI, 0.3 to 14.5), there was no support for an association with APOE genotypes. The results of this cross-sectional study support the need for a prospective study of genetic factors, such as APOE promoter polymorphisms, and the incidence of and sequelae from concussions in college athletes.     

Pulmonary embolism after hip or knee replacement: postoperative changes on pulmonary scintigrams in asymptomatic patients

Serial pulmonary imaging has proved to be effective in the evaluation of patients undergoing total joint arthroplasty. A clinical dilemma arises in asymptomatic patients whose postoperative pulmonary images differ from the preoperative images. The authors prospectively evaluated 403 patients with serial imaging to determine the significance of changed postoperative images in asymptomatic patients undergoing total hip or knee arthroplasty. Twenty-two (5.5%) patients had significant changes on postoperative images. Seventeen were asymptomatic; all but one underwent pulmonary angiography. Documented pulmonary emboli were demonstrated in 100% of patients whose postoperative images changed to indicate a high probability of pulmonary embolism, 71% whose images changed to a moderate probability, and 0% whose images changed to indeterminate probability. Overall, pulmonary emboli occurred in 76% of all asymptomatic patients with significantly change postoperative images. Asymptomatic pulmonary embolism is a significant occurrence after total hip or knee repair, and a changed lung scan with appropriate clinical evaluation is an accurate indicator of pulmonary emboli in asymptomatic postarthroplasty patients.     

Accuracy of digital imaging interpretation on an 1K × 1K PC-based workstation in the emergency department

The purpose of this study was to evaluate the accuracy of interpretation of digital radiographs on 1K × 1K PC-based workstations and compare it to that of 2K × 2K workstations in our filmless emergency department. We reviewed 1013 studies, of which 404 were chest, 133 abdominal, and 476 musculoskeletal. All studies were interpreted prospectively on the 1K × 1K workstation, and the findings were compared to those on the 2K × 2K diagnostic workstation which served as the control. Among all the studies performed, 515 were negative (255 chest, 91 abdominal, and 169 musculoskeletal). Another 498 had positive findings (149 chest, 42 abdominal, and 307 musculoskeletal). When the cases were reviewed on the 1K × 1K monitor, the diagnosis was missed in 5 of the 149 positive chest cases (3.35 %), in 5 of the 307 positive musculoskeletal cases (1.63 %), and in none of the 42 positive abdominal cases (0 %). In total, we misinterpreted 10 of the 498 positive cases (2.01 %). The miss rate of the 1K × 1K clinicians' review station is low and acceptable for its stated purpose. However, we doubt that it can be used for primary diagnostic purposes.     

预激态补骨脂素抑制 K562细胞增殖的实验研究

本研究的目的是观察预激态补骨脂素对K562细胞增殖的影响，为补骨脂素的临床应用提供实验依据。取预激态补骨脂素和晚激态补骨脂素处理的细胞，在培养后检测台盼蓝拒染细胞数和白血病细胞集落，并对它们在台盼蓝拒染细胞抑制率(TBIR)、细胞增殖抑制率(CPIR)和集落形成抑制率(CFIR)方面的差异进行比较。结果表明：预激态补骨脂素对K562细胞增殖有抑制作用；随着预激态补骨脂素浓度的增加，其抑制作用也随之增强；预激态补骨脂素与晚激态补骨脂素的TBIR、CPIR、CFIR各值比的差异不显著；为使预激态补骨脂素要充分发挥对K562细胞的抑制作用，补骨脂素的紫外线照射时间应在10分钟以上；与K562细胞作用时间也应大于12小时；抑制作用会因预激态补骨脂素预激后搁置时间的延长而下降，在6小时内作用最强。结论：预激态补骨脂素和晚激态补骨脂素对K562细胞的增殖均表现出抑制作用，有望作为临床的抗肿瘤用药。     

Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells.

Vascular endothelial growth factor (VEGF) is a mitogen with a specificity for endothelial cells in vitro and an angiogenic inducer in vivo. We tested the hypothesis that VEGF may confer on expressing cells a growth advantage in vivo. Dihydrofolatereductase--Chinese hamster ovary cells were transfected with expression vectors which direct the constitutive synthesis of VEGF. Neither the expression nor the exogenous administration of VEGF stimulated anchorage-dependent or anchorage-independent growth of Chinese hamster ovary cells in vitro. However, VEGF-expressing clones, unlike control cells, demonstrated an ability to proliferate in nude mice. Histologic examination revealed that the proliferative lesions were compact, well vascularized, and nonedematous. Ultrastructural analysis revealed that capillaries within the lesions were of the continuous type. These findings indicate that the expression of VEGF may confer on cells the ability to grow in vivo in the absence of transformation by purely paracrine mechanisms. Since VEGF is a widely distributed protein, this property may have relevance for a variety of physiological and pathological proliferative processes.     

Diabetic retinopathy: a leading cause of new blindness

Some of the basic underlying processes in the development of diabetic retinopathy include changes in the walls of retinal vessels, with occlusion and leakage. These result in edema, hemorrhage, hard exudates, plaques, and ischemia, leading to neovascularization. When proliferative retinopathy supervenes, it may result in complete blindness. Internists and family practice physicians should be alert for early signs of diabetic retinopathy. Ideally, diabetic patients should have their eyes examined yearly by an ophthalmologist. A fundus examination without dilation and usually without acuity testing rarely detects proliferative or early background retinopathy. Multicenter studies have shown that photocoagulation of new vessels with the argon laser may significantly reduce the incidence of severe visual loss. This treatment method has the potential of reducing the incidence of diabetic blindness by 60% to 80%. Photocoagulation is not a "cure" for diabetic macular edema; when used judiciously, however, it can sometimes further reduce visual loss caused by this common disease. The course of diabetic retinopathy in individual cases is unpredictable. After photocoagulation, some patients cannot see as well as before, though in others the progress of the disease is arrested. There is a conservative concern about a procedure that destroys retinal tissue in the hope of limiting the progression of the disorder. Yet photocoagulation appears to be the only alternative until a better treatment is developed through basic research.     

Donor screening for antibody to hepatitis B core antigen and hepatitis B virus infection in transfusion recipients

BACKGROUND: Testing for antibody to hepatitis B core antigen (anti-HBc) as a surrogate for hepatitis C viremia is no longer needed for blood donor screening. Currently, the important question is how much its use supplements hepatitis B surface antigen (HBsAg) donor screening in preventing transfusion-transmitted hepatitis B virus (HBV) infection. STUDY DESIGN AND METHODS: In a study conducted in the 1970s, 64 blood donors were associated with 15 cases of HBV (1.0%) in 1533 transfusion recipients. Sera from 61 donors at donation and 29 follow-up visits were available for present-day assays for HBsAg, HBV DNA, anti-HBc, and antibody to HBsAg (anti-HBs). RESULTS: HBsAg was found in four previously negative blood donors; HBV DNA was limited to three of these four. Anti-HBc was detected in six HBsAg-negative donors. Two other donors were negative in all assays at donation, but positive for anti- HBc and anti-HBs 2 to 4 months later. The remaining donors were negative for all HBV markers, which left five recipient cases unexplained. No HBV transmission was observed when anti-HBs sample-to- negative control values were > or = 10. CONCLUSION: Some 33 to 50 percent of cases of hepatitis B that could be transmitted by transfusion of blood from HBsAg-negative donors are prevented by anti- HBc screening. Anti-HBc-positive donors unequivocally positive for anti- HBs should be considered noninfectious for HBV and should be allowed to donate. Anti-HBc screening of paid plasmapheresis donors, supplemented by anti-HBs testing, would reduce the amount of HBV to be processed by virus inactivation and increase the content of anti-HBs in plasma pools.